Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 972 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
View directory record Official record
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 16, 2026, 5:25 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

NCT00621478
View directory record Official record
Conditions
Status Epilepticus
Interventions
lorazepam or diazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 18 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

NCT03229759
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Octenidine Dihydrocloride in aqueous solution, Vehicle Control, Saline Control
Drug · Other
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

NCT00326586
View directory record Official record
Conditions
Prostate Cancer
Interventions
AR Antagonist (BMS-641988)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin and Affect Processing in Posttraumatic Stress Disorder

NCT02546570
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 16, 2026, 5:25 PM EDT
Withdrawn Phase 3 Interventional

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

NCT02219373
View directory record Official record
Conditions
Pediatric Chronic Neuropathic Pain
Interventions
Gabapentin, Oxcarbazepine, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines

NCT05089851
View directory record Official record
Conditions
Wrinkles, Photoaging, Fine Lines
Interventions
Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Combination Product
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 16, 2026, 5:25 PM EDT
Withdrawn Not applicable Interventional

Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain

NCT00945620
View directory record Official record
Conditions
Pain Control
Interventions
ropivicaine, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 16, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional

GW873140 In Combination With Combivir In HIV Infected Subjects

NCT00104429
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW873140, Combivir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
27
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

NCT02055118
View directory record Official record
Conditions
Hunter Syndrome
Interventions
idursulfase-IT, No IT treatment
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 16, 2026, 5:25 PM EDT
Active, not recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 5:25 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery

NCT02747875
View directory record Official record
Conditions
Opioid Use, Unspecified
Interventions
Methadone, Fentanyl
Drug
Lead sponsor
Andrew Waberski
Other
Eligibility
2 Years to 7 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

NCT00243789
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Pentoxifylline
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
7 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 16, 2026, 5:25 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 16, 2026, 5:25 PM EDT
Withdrawn Phase 4 Interventional

Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

NCT02773797
View directory record Official record
Conditions
COPD
Interventions
IN-DEX 1.0 mcg/kg, intranasal saline, IN-DEX 1.5 mcg/kg, intranasal saline, Placebo - Saline
Drug
Lead sponsor
Dayton VA Medical Center
Federal
Eligibility
45 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCT01192880
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Bitopertin, Antipsychotics
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 16, 2026, 5:25 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans II

NCT07043452
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3, Blinded Study Medication - Condition 4, Blinded Study Medication - Condition 5, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 16, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery

NCT02206685
View directory record Official record
Conditions
Thoracolumbar Scoliosis
Interventions
Methadone, Normal Saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 17 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 16, 2026, 5:25 PM EDT
Terminated Phase 4 Interventional Results available

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

NCT01070888
View directory record Official record
Conditions
Exercise Induced Asthma
Interventions
Budesonide/Formoterol, Budesonide
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 16, 2026, 5:25 PM EDT